Kehoe Siobhan M, Eisenhauer Eric L, Abu-Rustum Nadeem R, Sonoda Yukio, D'Angelica Michael, Jarnagin William R, Barakat Richard R, Chi Dennis S
Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, MRI-1026, New York, NY 10021, USA.
Gynecol Oncol. 2009 Mar;112(3):496-500. doi: 10.1016/j.ygyno.2008.10.011. Epub 2008 Dec 17.
To determine the incidence, management, and outcome of patients diagnosed with a pancreatic leak after a distal pancreatectomy during primary surgical cytoreduction for ovarian, peritoneal, or tubal cancer.
We performed a retrospective chart review of all patients who had a distal pancreatectomy at the time of primary surgery. Charts were reviewed to identify those patients who developed a persistent left upper quadrant abdominal fluid collection with elevated amylase levels.
A total of 17 patients had a distal pancreatectomy; of these, 4 patients (24%) developed a postoperative pancreatic leak. In these patients, persistent leukocytosis prompted evaluation with a computed tomography scan, which subsequently revealed a fluid collection. The median time from surgery to drainage of this collection was 9 days (range, 8-66). The drain remained in situ for a median of 29 days (range, 22-82). The median amylase level of the fluid was 22,945 U/L (range, 763-47,250). The median length of hospital stay for those patients with a leak was 33 days (range, 25-44), which was longer than those without a leak. However, the median time from surgery to treatment with systemic chemotherapy was 31 days (range, 16-43), which was equivalent to those without a pancreatic leak.
Twenty-four percent of patients who had undergone a distal pancreatectomy developed a pancreatic leak. This complication, which usually presents early in the postoperative period, can be managed conservatively with percutaneous drainage. Oral intake may be resumed, and total parenteral nutrition is not needed in the majority of cases. Systemic chemotherapy can be administered without significant delay.
确定在卵巢癌、腹膜癌或输卵管癌初次手术细胞减灭术中接受远端胰腺切除术后被诊断为胰瘘的患者的发生率、处理方法及预后。
我们对所有在初次手术时接受远端胰腺切除术的患者进行了回顾性病历审查。审查病历以确定那些出现左上腹持续性积液且淀粉酶水平升高的患者。
共有17例患者接受了远端胰腺切除术;其中4例(24%)发生了术后胰瘘。在这些患者中,持续的白细胞增多促使进行计算机断层扫描评估,随后发现了积液。从手术到该积液引流的中位时间为9天(范围8 - 66天)。引流管中位留置时间为29天(范围22 - 82天)。积液的中位淀粉酶水平为22,945 U/L(范围763 - 47,250)。有胰瘘患者的中位住院时间为33天(范围25 - 44天),长于无胰瘘患者。然而,从手术到全身化疗的中位时间为31天(范围16 - 43天),与无胰瘘患者相当。
接受远端胰腺切除术的患者中有24%发生了胰瘘。这种通常在术后早期出现的并发症可通过经皮引流进行保守处理。大多数情况下可恢复经口进食,无需全胃肠外营养。全身化疗可无显著延迟地进行。